Clinical Trial Update: Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease [Phase 2]

View source ↗

Summary

A Phase 2 long-term extension study of ACC-001 in Japanese subjects with mild-to-moderate Alzheimer's disease was terminated; results related to safety, tolerab…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• ACC-001

Snippet

Sponsor: Pfizer | Conditions: Alzheimer's Disease | Phase 2 | Status: TERMINATED | Results posted: 2014-12-22